Vamicamide

Vamicamide

Clinical data
Other names	Urocut, FK-176
Legal status
Legal status	Investigational
Identifiers
IUPAC name (2R,4R)-4-(dimethylamino)-2-phenyl-2-pyridin-2-ylpentanamide
CAS Number	132373-81-0
PubChem CID	65967
ChemSpider	59369
UNII	RU10K34QRU
ChEMBL	ChEMBL2114366
Chemical and physical data
Formula	C18H23N3O
Molar mass	297.402 g·mol−1
3D model (JSmol)	Interactive image
SMILES C[C@H](C[C@@](C1=CC=CC=C1)(C2=CC=CC=N2)C(=O)N)N(C)C
InChI InChI=1S/C18H23N3O/c1-14(21(2)3)13-18(17(19)22,15-9-5-4-6-10-15)16-11-7-8-12-20-16/h4-12,14H,13H2,1-3H3,(H2,19,22)/t14-,18-/m1/s1 Key:BWNLUIXQIHPUGO-RDTXWAMCSA-N

Vamicamide, also known as FK-176 or Urocut, is a muscarinic acetylcholine receptor (mAChR) antagonist that was developed by Fujisawa (now part of Astellas Pharma) for the treatment of urinary incontinence and overactive bladder. ^[1] This small molecule drug acts by blocking muscarinic receptors, which play a role in bladder function. Despite showing promise in preclinical studies for increasing bladder capacity without affecting other urinary parameters, ^[2] vamicamide has never been approved for medical use. The drug's development was ultimately discontinued, with its highest research and development status reaching the New Drug Application (NDA) phase in Japan. ^[1]

References

1. "Vamicamide". PatSnap.
2. Yamamoto T, Koibuchi Y, Miura S, Sawada T, Ozaki R, Esumi K, Ohtsuka M (December 1995). "Effects of vamicamide on urinary bladder functions in conscious dog and rat models of urinary frequency". The Journal of Urology. 154 (6): 2174–8. doi:10.1016/S0022-5347(01)66723-5. PMID   7500484.